Oregon State University College of Pharmacy

RESEARCH & SCHOLARSHIP

IN PHARMACEUTICAL SCIENCES







WELCOME

The Department of Pharmaceutical Sciences at Oregon State University is located on two campuses, in the Robertson Life Sciences Building on the Waterfront in Portland at Oregon Health & Sciences University and in buildings across the Oregon State University campus in Corvallis from Weniger Hall, to the Linus Pauling Science Center, to our historical home in the Pharmacy building. This geographic diversity allows us to collaborate broadly with scientists and clinicians at both OSU, Oregon's land grant university, and OHSU, the state's major medical research center, to promote translation of research to improve health for all.

We are currently composed of 21 faculty, 34 PhD students, and a crew of postdoctoral scholars, research assistants, undergraduate researchers, and visiting scientists from across the country and the globe. In this brochure, you will find descriptions of the expertise and areas of research explored in our department. Our research mission is to educate and train the next generation of leaders and innovators in pharmaceutical sciences research to discover and develop tools and strategies for prevention, detection, and cure of human disease. An exciting new opportunity for us is the recent funding of an NIH graduate student training grant to support education and research into medicinal natural products. We are proud of our accomplishments and look forward to a bright future.

Theresa Filtz, Department Chair

OREGON STATE UNIVERSITY COLLEGE OF PHARMACY

GREATING

- CONTENT -

- 4 DRUG DISCOVERY
- 10 PHARMACEUTICAL MICROBIOLOGY
- 12 COMPUTATIONAL & SYSTEMS PHARMACEUTICAL
 - SCIENCES
- 16 GENETIC MODELS OF DISEASE & DRUG
 - TARGET DISCOVERY
- 20 HIGH THROUGHPUT DRUG DISCOVERY
 - SCREENING SERVICES LABORATORY
- 22 NANOTHERAPEUTICS

DISCOVERY

Our medicinal chemists are focused on developing medicines from natural sources. By isolating novel chemicals from plants or marine bacteria, they hunt for anti-cancer compounds, new antibiotics, novel anti-malarials, natural sunscreens and agents that might treat diabetes or even slow the aging process. Using bacteria, they are researching ways to biosynthesize novel compounds in greater abundance.





JANE ISHMAEL, PH.D.

focused on solving the mechanism of pipeline has resulted in the discovery in the area of natural product drug research goal is to identify and validiscovery. We take advantage of the date new biological targets to inspire College of Pharmacy High Through- new cancer treatments. put Screening Facility to identify and advance new bioactive molecules to

Research in the Ishmael laboratory is early stage preclinical evaluation. This action of experimental compounds and pharmacological evaluation of a that have potential utility against treat- number of new chemical entities that ment-resistant human cancers. These disrupt cell signaling pathways and instudies are part of an ongoing collab- duce survival responses such as autooration with OSU colleagues working phagy or "self-eating". Our long-term

TAIFO MAHMUD, PH.D.

Dr. Mahmud's research interests focus on natural product-based drug discovery and development. His group employs a multidisciplinary approach that utilizes cutting-edge technologies in molecular genetics, enzymology, and chemistry to produce novel pharmaceuticals. Currently, a number of research projects are being pursued in his laboratory. Those include (1) engineered production of antibiotics, antimalarial, and anticancer drugs, (2) investigation of novel enzymes and their products through genome mining, (3) discovery and development of natural sunscreen compounds, and (4) investigation of new bioactive compounds from Indonesian medicinal plants and rare microbes. Some recent accomplishments of his group include discovering two new families of enzymes with unique catalytic mechanisms and developing natural productbased antimalarial, anticancer, and sunscreen compounds through genetic engineering or synthetic biology.




LAST YEAR

FACULTY PUBLISHED

93 ARTICLES

IN PEER REVIEWED

JOURNALS








J. FRED STEVENS, PH.D.

Research in the Stevens laboratory is aimed at determining the role and function of vitamins and dietary phytochemicals in human health and disease. Dr. Stevens' research is closely aligned with the research mission of the Linus Pauling Institute at OSU (http://lpi.oregonstate. edu/). Mass spectrometry-based metabolomics and metabolic labeling are new directions in the Stevens laboratory for discovery of biological effects and mechanisms of actions of natural compounds in cell culture and animal models of disease as well as in humans.

Current projects include: Xanthohumol for mitigation of metabolic syndrome and inflammatory bowel disease; Vitamin C in mitigation of cardiovascular disease; Brain stimulants from the medicinal herb, Centella asiatica, in the fight against Alzheimer's disease; and Bioactives from the oilseed crop, meadowfoam (Limnanthes alba).

6 | OSU COLLEGE OF PHARMACY





KERRY MCPHAIL, PH.D.

to be a source of novel, evolutionarily- and sponges on marine reefs, or in uniquely specialized bacteria and secretion of proteins from cells, which fungi found in unusual environments is important in all organisms. or at habitat interfaces, such as within

Microbial natural products continue the sapwood of trees, in tunicates optimized molecular structures stromatolites ('living rocks') at the with important biological activities, edges of the ocean or hypersaline particularly relevant to cancer and lakes. In particular, we focus on the infectious diseases, that may lead to the molecular structure elucidation of development of new pharmaceutical natural product macrocycles that have drugs. Dr. McPhail's group investigates potential anti-cancer or antimicrobial the natural products chemistry of applications because they affect the



RICHARD B. VAN BREEMEN, PH.D.

Dr. Van Breemen is currently Director neurological degenerative diseases. health and prevent cancer and from basic science to clinical trials.

of the Linus Pauling Institute at This research integrates the analytical OSU. Aligned with the Linus Pauling tool of mass spectrometry into all Institute, research in the van Breemen aspects of the drug discovery and laboratory concerns the discovery development from screening of and development of natural products botanical extracts for the identification as chemoprevention agents and of active natural products, to studies the investigation of mechanisms of of drug metabolism and disposition, action and safety of botanical dietary and to quantitative analyses of the supplements. Our goal is to identify bioavailability and pharmacokinetics of micronutrients and natural products pharmacologically active compounds. that may be used to maintain optimal These translational studies extend



BENJAMIN PHILMUS, PH.D.

discovery and production of natural cuses on establishing a lab-friendproducts, small molecules made by ly, scalable surrogate bacterial host bacteria, fungi, plants and animals. (Anabaena sp. PCC 7120) that we can We work primarily with cyanobacteria use as an environmentally friendly (formerly known as blue-green algae) compound production scaffold. as they are known to produce a wide My lab is also researching how these range of natural products that have complex structures are assembled diverse biological activities. While bio- and looking for ways to exploit these active cyanobacterial compounds can reactions and perform complex reacbe obtained by collection and isolation tions in environmentally benign ways. of environmental samples or through

The Philmus lab is interested in the chemical synthesis, our research fo-



PHIL PROTEAU, PH.D.

The main projects being pursued in fungal diterpene synthase products. project involves characterization of Southern Oregon University).


the Proteau laboratory involve aspects Diterpenes are a class of compounds of the chemistry and biology of natural that often have interesting biological products. One project is aimed at the properties. The ability to predict a exploration of antibiotic compounds diterpene structure from the sequence from cyanobacteria. Cyanobacteria of its corresponding diterpene produce a variety of peptide and synthase enzyme is not yet possible. amino acid derived compounds with However, by characterizing unknown antifungal/antialgal properties that diterpene synthase products, we are being investigated in collaboration hope to gain insight into this problem. with Dr. Benjamin Philmus. Another (collaboration with Dr. Patrick Videau,

8 | OSU COLLEGE OF PHARMACY 2019 RESEARCH | 9



PHARMACEUTICAL MICROBIOLOGY

Good and bad, bacteria live with us. Faculty in pharmaceutical microbiology are searching for new ways to treat gonorrhea and other infectious diseases that are becoming resistant to existing antibiotics. Faculty are also curious about how the trillions of bacteria that live with us in our gut and elsewhere alter our susceptibility to diseases such as advanced cervical cancer, anxiety, or diabetes. As described in the next section, a couple of our computational and systems biology researchers in Pharmaceutical Sciences are also a part of the Pharmaceutical Microbiology group.





ALEKSANDRA SIKORA, PH.D.

gen discovery program which includes the Sikora laboratory.

The Sikora research team takes multi- comprehensive proteomics coupled disciplinary approaches to develop ther- with bioinformatics. Candidate antigens apeutic interventions against sexually are assessed for their suitability for intransmitted infection, gonorrhea. Gon- clusion in a vaccine. We further assess orrhea affects nearly 78 million of people their structure-function to learn about worldwide and has serious consequenc- the fascinating biology of the bacterium es on reproductive and neonatal health. responsible for gonorrhea. Drug discov-There is a dire possibility of untreatable ery through high-throughput screening gonorrhea due to rapid increase in an- of small molecule inhibitors that target tibiotic resistance. Accordingly, to devel- central players in bacterial physiology op gonorrhea vaccine(s), we apply anti- and pathogenesis are a second focus of

COMPUTATIONAL AND SYSTEMS PHARMACEUTICAL SCIENCES

Faculty with expertise in statistics and computational approaches are mining large data sets to better understand the relationship between molecular events, the bacteria that live in us, and our susceptibility to diseases.





ANDREY MORGUN, PH.D.

host functions; 2) Which of those germfree experimentation. mechanisms play role in diseases we

Efforts in the Morgun lab are focused study; 3) Do environmental factors on the understanding how the such as antibiotics and other drugs as interplay between host and microbiota well as host genetics alter microbiota contributes to pathogenesis and in a manner that it acquires properties treatment of diseases such as type which are harmful or beneficial to 2 diabetes, immunodeficiency, and host? To answer these questions we cervical cancer. The key questions are: use Systems Biomedicine approaches 1) Which components of microbiota by combining large scale omics and drive specific immune and other network biology with gnotobiotics/

"My laboratory works on modelling gut microbiota interactions with the environment and its host, to unravel how it impacts our behavior" -Maude David



MAUDE DAVID, PH.D.

Dr. David's laboratory studies gut-brain interactions to understand how the gut microbiota can impact our behavior, specifically in Autism Spectrum Disorder and Generalized Anxiety Disorder. She uses a crowd-sourced approach to collect lifestyle information, dietary habits, and microbiome samples. Her team also works on identifying bottlenecks in microbiome data exploration and has been developing new biocomputing methods to improve sequencing data annotation and analysis. Her interest lies in using machine learning algorithms to extract meaningful information from massive datasets already publicly available such as the Human Microbiome Project.



KEVIN BROWN, PH.D.

Dr. Brown is a complex systems scientist. He studies complex biological systems, particularly those arising in systems biology, systems neuroscience, and cognitive science. He is the originator of "Sloppy Models," a theory of parameter space geometry in large nonlinear models with many underdetermined parameters, such as those that arise when modeling signaling dynamics in biological cells. He studies networks in molecular biology, neuroimaging, and cognitive science, and is particularly interested in trying to determine the link between structure and function in complex networks. He employs both data-driven and model-driven approaches to problems, and he has many productive collaborations with experimentalists.

GRADUATE STUDENT AVVARDS



BRIANNA COTE

PHARMD/ PH.D.

A Ph.D. degree candidate in Dr. Adam Alani's Pharmaceutics lab who holds a Pharm.D. degree, Brianna Cote is the recipient of successive nationallycompetitive fellowships. Dr. Cote was awarded an American Association of Pharmaceutical Sciences (AAPS) Graduate Student Fellowship last year. This year, she was the recipient of the Dr. Paul B. Myrdal Memorial Pre-Doctoral Fellowship in Pharmaceutics from the American Foundation for Pharmaceutical Education (AFPE). In addition, Dr. Cote has also received an Oregon Lottery Scholarship.



DAVID GALLEGOS

PH.D.

A recently graduated PhD student from the natural products laboratory of Dr. Kerry McPhail, won the Kilmer Prize from the American Society of Pharmacognosy, a nationally competitive award with a single recipient every year.



EVAN CARPENTER

PH.D.

A 4th year PhD student in the skin cancer lab of Dr. Arup Indra, won the Eugene M. Farber Travel Award for Young Investigators to attend the Society for Investigative Dermatology national meeting.



DANIEL NOSAL & LUYING CHEN

PH.D.

Both advanced PhD transfer students in the van Breemen laboratory, won Young Investigator travel awards to attend the conference and short course on "Mass Spectrometry: Applications to the Clinical Lab" in 2019.



ADEL AL FATEASE

PH.D.

A 5th year PhD student in the Nanotherapeutics lab of Dr. Oleh Taratula, won the Holt Fellowship award from the College of Pharmacy and the "Outstanding podium presentation" award at the OHSU research week in May 2018.

16 | OSU COLLEGE OF PHARMACY

GENETIC MODELS OF DISEASE & DRUG TARGET DISCOVERY

The hunt for new disease treatments requires an understanding of disease and development at the molecular levels. Faculty in pharmacology are studying development and growth of muscles, skull bones, skin and thymocytes to better understand congenital birth defects, type II diabetes and obesity, wound-healing, leukemia and skin cancer.



MARK LEID, PH.D.

the role of the transcription factor interactome and mechanisms by which CTIP2/BCL11B in development post-translational modifications, such of the craniofacial skeleton and as phosphorylation, sumoylation, maintenance of sutural plasticity. Mice and ubiquitination, control the lacking BCL11B, which were created in transcriptional regulatory activity of the lab, are a model for the human BCL11B in all cell types. disease known as craniosynostosis, a condition characterized by premature ossification of cranial sutures.


The Leid laboratory is focused on We are defining the BCL11B




CHRISSA KIOUSSI, PH.D.

The Kioussi laboratory is interested in cell its distinct characteristics, function

defining the gene regulatory networks and behavior. We use a combination involved in muscle development and of biochemical, genetics, genomic and energy balance systems towards the computational approaches to disgoal of developing new strategies to sect the roles of transcription factors treat dystrophies and metabolic syn- involved in organ development and dromes. A complex transcriptional net-tissue regeneration. Our studies will work transforms stem cells, through serve as the foundation for developan organized series of embryonic cell ment of future strategies and pharmatypes, into adult cell types. Genetic cological interventions that influence variation is a major cause of develop- the maintenance and differentiation ment, diversity and disease suscepti- potential of cell populations in pability. Epigenome determines the pat- tients with disrupted metabolic fuel tern of gene expression and gives the homeostasis and muscle atrophy.











Transgenic mouse embryos. Colors indicate the expression profile of genes in the nervous and muscular systems.

COLLEGE INVESTIGATORS SUBMITTED 99 GRANT PROPOSALS, REQUESTING OVER \$58M IN TOTAL COSTS.









Co-expression of Stem cell marker Keratin 15 and Proliferation cell nuclear antigen (PCNA) during wound healing process.



GITALI INDRA, PH.D.

new generation materials such as Gombart, Indra A and Leid.

Indra lab focuses on wound healing electro-spun nanofibers which are and regeneration process and coated with these identified molecules particularly studies the effects of adult for advanced applications such as in bulge hair follicle stem cells (HFSC) in diabetic and chronic wound model wound healing and also identifying to promote healing process. Splinting the molecular and cellular mechanism Strategies are also being used to of repair in acute and chronic wounds. overcome wound contraction in Lab has identified several molecules animal models so that it can relate consisting of growth factors and to healing mechanism in humans. cytokines. The lab is currently using Working in Collaboration with Drs .Xie,



ARUP INDRA, PH.D.

for therapeutic interventions. We are Yale, Harvard and UC Berkeley. studying the protective role of skin

My laboratory is interrogating pigmentation against deleterious how skin "stem cells" suppress effects of UV-radiation e.g. photoaging inflammatory skin disease (e.g. and melanoma skin cancer. eczema) and protect against infections Mechanisms of immune-evasion in by regulating lipid metabolism and different cellular compartments to modulating cell-cell communications. promote melanoma invasion and Using genetic tools and molecular metastasis are actively explored. approaches we discovered new We have generated pre-clinical pathways controlling formation of a models mimicking atopic dermatitis, healthy skin, and investigating how skin pigmentation disorder, and "lipids" act as precision biomarkers melanomas in humans. Collaborators for eczema progression and utilized include scientists from OSU, OHSU,



30%





THERESA FILTZ, PH.D.


messages to changes in protein activities and/or changes in gene transcription programs. We search for

Research in the Filtz lab focuses on new drug targets by trying to better better understanding the means by understand the array of changes called which cells respond to signals that post-translational modifications that cause them to alter their activities may alter gene transcription. We are or states. Cells receive message currently interested in a transcription from the outside at receptors on the factor known as Bcl11b that is highly cell membrane and then a series of modified and that is associated with intracellular events converts those lymphomas and childhood leukemia.

20 | OSU COLLEGE OF PHARMACY 2019 RESEARCH | 21

HIGH-THROUGHPUT DRUG DISCOVERY LABORATORY

Research in the department and college is supported by the High-throughput Drug Discovery Laboratory in which biochemical and cell-based assays are completed with the aid of robotic liquid handlers, a high-content imaging system, and screening analysis software to identify biomodulators.








DYLAN NELSON

ing Services Laboratory was estab- such as fungi, bacteria, and plants. lished in 2016 to provide the research. The robotic systems allow researchcommunity with access to robotic sys- ers to test thousands of samples per tems and chemical libraries for drug day. The lab is available to academic, discovery. Located on the first floor non-profit, and for-profit researchers. of the Pharmacy Building on the Cor- Graduate students and post-doctoral vallis campus, the chemical libraries researchers are able to be trained to total about 300,000 compounds and work in the lab and develop valuable include FDA approved drugs, charac- skills in automation and modern drug terized bioactive molecules, unchar- discovery methods. acterized small molecules, and chem-

The College's High-Throughput Screen- ical extracts from biological sources

PHARMACEUTICS & NANOTHERAPEUTICS

Novel types of drugs such as antibodies and RNA require new methods to deliver these agents effectively and selectively in the body. Faculty are using nanotechnology to encapsulate anti-cancer drugs and target specific tissues, build nanoscale particles to light up and kill cancer cells with heat, help reverse muscle wasting in cancer chemotherapy, find new ways to deliver gene therapy to cystic fibrosis patients, and limit side effects from radiation therapy.





ADAM WG. ALANI, PH.D.

Dr. Alani's research focuses on the design of nanoscale drug delivery systems for been directly involved in nanoscale delivery to the lymphatic system. formulation, characterization, toxicity,

efficacy, pharmacokinetics evaluation both in vitro and in vivo models and therapeutic and diagnostic applications. scale-up. He views his work as translating The work in his lab involves the field of bench side research into viable treatment designing and formulating nanoscale options. Currently the work in the Alani systems for the delivery of difficult to lab focus on cancer therapy, specifically formulate molecules for the treatment utilizing nanotherapy for targeting tumor of cancer and other diseases. He has microenvironment and small molecules



J. MARK CHRISTENSEN, PH.D.

Recently retired as an Emeritus Professor, Dr. Christensen continues research focused and drug formulation. In response to the growing demand for drug therapy for animals, Dr. Christensen studies drug disposition in various animals in collaboration with faculty from the College of Veterinary Medicine. Similar techniques

are applied to determining appropriate drug dosing and drug disposition in on biopharmaceutics, pharmacokinetics humans, including the means and routes of absorption, metabolism and elimination. Research into the sustained action of oral dosage forms with respect to performance, production, and in vivo characteristics is another area of interest.





OLEH TARATULA, PH.D.

The research in Oleh Taratula's Lab, to targeted cells or proteins. The lab a promising approach for transporting developed nano-drugs to clinical use. agents of interest (drugs, genes, imaging probes, hyperthermia, etc.), specifically

located in the Robertson Life Sciences collaborates within the OSU College Building in Portland, focuses on the of Pharmacy, and externally with the development of nanomaterial-based, Earle A. Chiles Research Institute at multifunctional drug delivery systems Providence Portland Medical Center, for application in diagnosis and Oregon National Primate Research treatment of cancer, endometriosis, Center, the Department of Pediatrics and cachexia. Employing nanomaterials in the School of Medicine, and others. to overcome drug delivery obstacles is The primary goal is translation of the



OLENA TARATULA, PH.D.

objective is to assist in the accurate patients.

Olena Taratula's research utilizes an diagnosis/location of cancer tissue interdisciplinary (organic chemistry, using innovative nano-imaging probes, biochemistry, and nanotechnology) with subsequent immediate treatment. approach toward the development Collaborations with the Carlson of effective imaging agents and College of Veterinary Medicine, OHSU nanomedicines, particularly for Biomedical Engineering, and OHSU cancer. This includes the development Dotter Interventional Institute provide of photo-theranostic agents for the opportunity for testing nano-agents use in image-guided surgery and in various animal models, including intraoperative therapy. The main rodents, rabbits, and domestic dog



GAURAV SAHAY, PH.D.

CRS Post Doc Award and received New Symposium. Investigator Awards from AACP and MRF. Sahay lab has been supported through

With members of his lab Dr. Sahay has NIH, Cystic Fibrosis Foundation, OSU unlocked the molecular mechanisms Foundation and several companies. Dr. involved in the intracellular delivery Sahay serves as a consultant to biotech of nanoparticles and designed new firms and is on the Scientific Advisory materials that target subcellular Board of Oncorus Therapeutics. He has compartments. The Sahay Lab has over 30 publications in top tier journals deployed non-viral vectors for gene including Nature Biotechnology, Nano therapy applications for treatment of Letters, Nature Nanotechnology etc., cystic fibrosis and other rare disorders. and chaired the 2018 International Dr. Sahay is the past winner of AAPS and Nanomedicine and Drug Delivery




CONROY SUN, PH.D.

combine treatment with medical imaging patients.

The Sun laboratory is focused on applying modalities, such as image-guided materials science and nanotechnology drug delivery. We are also developing toward unmet needs in cancer care. imaging probes and techniques to Our expertise lies in the development improve detection, diagnosis, and of novel biomaterials for tumor targeted evaluation of cancer treatments. As drug delivery and molecular imaging. In interdisciplinary scientists, we maintain this work, we exploit the multifunctional active collaborations spanning the capabilities of nanoparticles to combine basic sciences (chemistry, physics conventional therapies, such as and biology) to clinicians (radiology, radiation and chemotherapy, to achieve radiation oncology and surgery) with the a synergistic treatment response or goal of translating novel technologies to

26 | OSU COLLEGE OF PHARMACY 2019 RESEARCH | 27



PHARMACY.OREGONSTATE.EDU